177 related articles for article (PubMed ID: 23522296)
1. Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.
Hansel DE; Miller JS; Cookson MS; Chang SS
Urology; 2013 Jun; 81(6):1123-30. PubMed ID: 23522296
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
3. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
4. Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
Das A; Cohen JE; Ko OS; Jordan BJ; Glaser AP; Auffenberg GB; Meeks JJ
J Urol; 2021 Mar; 205(3):693-700. PubMed ID: 33021430
[TBL] [Abstract][Full Text] [Related]
5. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience.
Rouprêt M; Yates DR; Varinot J; Phé V; Chartier-Kastler E; Bitker MO; Compérat E
Can J Urol; 2012 Oct; 19(5):6459-64. PubMed ID: 23040628
[TBL] [Abstract][Full Text] [Related]
6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
7. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
11. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
12. [Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].
Neuzillet Y; Colin P; Comperat E; Dubosq F; Houede N; Larre S; Masson-Lecomte A; Pignot G; Puech P; Roumiguie M; Xylinas E; Mejean A; Roupret M
Prog Urol; 2016 Mar; 26(3):181-90. PubMed ID: 26777686
[TBL] [Abstract][Full Text] [Related]
13. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
[TBL] [Abstract][Full Text] [Related]
14. Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Study.
Kim BW; Ha YS; Lee JN; Kim HT; Kim TH; Lee JK; Byun SS; Choi YD; Kang HW; Yun SJ; Kim WJ; Kwon YS; Kwon TG
Urol J; 2015 Sep; 12(4):2233-9. PubMed ID: 26341764
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder - a study of 22 cases from a single cancer center.
Zhong H; George S; Kauffman E; Guru K; Azabdaftari G; Xu B
Diagn Pathol; 2014 Nov; 9():222. PubMed ID: 25425482
[TBL] [Abstract][Full Text] [Related]
16. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
17. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
18. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
19. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
20. Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate.
Cauberg EC; Mamoulakis C; de la Rosette JJ; de Reijke TM
World J Urol; 2011 Aug; 29(4):503-9. PubMed ID: 21350871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
